Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A pivotal trial assessing BRII-835 (VIR-2218) and BRII-179 (VBI-2601) Combination Therapy

Next Previous
X
Search
Trial Profile

A pivotal trial assessing BRII-835 (VIR-2218) and BRII-179 (VBI-2601) Combination Therapy

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 25 Mar 2022

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Elebsiran (Primary) ; VBI 2601 (Primary)
  • Indications Hepatitis B
  • Focus Registrational; Therapeutic Use

    • Most Recent Events

    • 25 Mar 2022 New trial record
    • 22 Mar 2022 According to a Brii Biosciences media release, if results of phase 2 combination study are positive the company plans to submit an Investigational New Drug Application (IND) application to China Center for Drug Evaluation (CDE) to initiate this pivotal study in 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top